
1. On a GAAP basis, second-quarter Abbott sales increased 39.5%.
2. Second-quarter GAAP diluted EPS was $0.66.
3. Second-quarter diluted EPS reflects over 105% growth versus the prior year.
4. Second-quarter diluted EPS from continuing operations on a GAAP basis reflects 120% growth.
5. Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $2.75 to $2.95. Abbott forecasts specified items for the full-year 2021 of $1.55 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, including expenses to align testing-related business with current and projected demand, expenses associated with acquisitions and other net expenses.
6. On a GAAP basis, Medical Devices sales increased 51.3%; Diagnostics sales increased 62.8%; Nutrition sales increased 11.9%; Established Pharmaceuticals sales increased 16.4%.
7. On a GAAP basis, FreeStyle Libre increased 53%.
8. On a GAAP basis, Global Adult Nutrition increased 18%.
9. On a GAAP basis, Diagnostics increased 63%.

**On a GAAP basis, second-quarter Abbott sales increased 39.5%.

Second-quarter GAAP diluted EPS was $0.66.

Second-quarter diluted EPS reflects over 105% growth versus the prior year.

Second-quarter diluted EPS from continuing operations on a GAAP basis reflects 120% growth.

Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $2.75 to $2.95. Abbott forecasts specified items for the full-year 2021 of $1.55 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, including expenses to align testing-related business with current and projected demand, expenses associated with acquisitions and other net expenses.

On a GAAP basis, Medical Devices sales increased 51.3%; Diagnostics sales increased 62.8%; Nutrition sales increased 11.9%; Established Pharmaceuticals sales increased 16.4%.

On a GAAP basis, FreeStyle Libre increased 53%.

World’s leading2 continuous glucose monitoring system has nearly 3.5 million users worldwide.

**Freestyle Libre**

- 43% growth in FreeStyle Libre on an organic basis

World’s leading2 continuous glucose monitoring system has nearly 3.5 million users worldwide.

**Nutrition**

- 16% growth in Adult Nutrition on an organic basis

Pandemic continues to raise awareness of how good nutrition and hydration support immune health

**Diagnostics**

- 57% growth on an organic basis

Partnership with United Airlines enables international travelers to use BinaxNOW™ Home Test and NAVICA™ app to return to the U.S. if they test negative

### Key Business Units

<table>
<thead>
<tr>
<th>Business Unit</th>
<th>Growth on an Organic Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Devices</td>
<td>+45.1%</td>
</tr>
<tr>
<td>Diagnostics</td>
<td>+57.2%</td>
</tr>
<tr>
<td>Nutrition</td>
<td>+9.5%</td>
</tr>
<tr>
<td>Established Pharma</td>
<td>+14.5%</td>
</tr>
</tbody>
</table>

**Full-Year 2021 Guidance Remains Unchanged**

Adjusted diluted EPS

$4.30 to $4.50

Reflects strong double-digit growth

**Second-Quarter 2021 Results**

Total Company Sales Worldwide

$10.2B

+35%¹

Reflects over 105% growth versus the prior year.

**Business Highlights**

- Growth in FreeStyle Libre on an organic basis
- World’s leading continuous glucose monitoring system has nearly 3.5 million users worldwide
- 43% growth in FreeStyle Libre on an organic basis
- Growth in Adult Nutrition on an organic basis
- Pandemic continues to raise awareness of how good nutrition and hydration support immune health
- 57% growth on an organic basis
- Partnership with United Airlines enables international travelers to use BinaxNOW™ Home Test and NAVICA™ app to return to the U.S. if they test negative

**Forward-Looking Statements**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.